Current Price Disclosure cycle – 2026 April
Page last updated: 19 December 2025
The 2026 April cycle has a data collection period of 1 April 2025 to 30 September 2025.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 11 November 2025.
The reduction day is 1 April 2026.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
Contents
- Outcomes of Price Disclosure calculations
- Flow-on price disclosure reductions
- Indicative prices of brands scheduled for a price disclosure reduction
- Confirmed prices of brands scheduled for a price disclosure reduction
- Brand price reductions and savings to patients
Outcomes of Price Disclosure calculations
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health, Disability and Ageing. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations will be published on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their December 2025 PBS approved ex‑manufacturer price (AEMP) and the weighted average disclosed price (WADP) was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2025 will also take the reduction on 1 April 2026 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The deadline to lodge a dispute is 12 January 2026.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices (WADPs) is presented in the table below.
|
Legal Instrument Drug |
Legal Instrument Form |
Legal Instrument MoA |
Brands of PI designated brands under 99ADHC (Y/N) |
Floor Price |
Price reduction applied in 2 previous cycles (Y/N) |
Average Unadjusted Price Reduction (UPR) at least 12.5% over 3 consecutive cycles (Y/N) |
December 2025 AEMP |
April 2026 AEMP |
Percentage difference between December 2025 and April 2026 AEMP (%) |
UPR threshold (%) |
Calculations based on: |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Abiraterone |
Tablet containing abiraterone acetate 250 mg |
Oral |
N |
- |
- |
- |
$876.42 |
$775.46 |
11.52% |
10% |
OWAPD |
|
Abiraterone |
Tablet containing abiraterone acetate 500 mg |
Oral |
N |
- |
- |
- |
$876.42 |
$775.46 |
11.52% |
10% |
OWAPD |
|
Adalimumab |
Injection 20 mg in 0.4 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$272.84 |
$240.89 |
11.71% |
10% |
GWAPD |
|
Adalimumab |
Injection 40 mg in 0.4 mL pre-filled pen |
Injection |
N |
- |
- |
- |
$444.17 |
$392.16 |
11.71% |
10% |
GWAPD |
|
Adalimumab |
Injection 80 mg in 0.8 mL pre-filled pen |
Injection |
N |
- |
- |
- |
$618.90 |
$546.43 |
11.71% |
10% |
GWAPD |
|
Amiodarone |
Tablet containing amiodarone hydrochloride 200 mg |
Oral |
Y |
$4.73 |
N |
Y |
$4.73 |
$4.00 |
16.07% |
10% |
GWAPD |
|
Anastrozole |
Tablet 1 mg |
Oral |
Y |
$7.26 |
N |
Y |
$7.26 |
$6.15 |
15.29% |
10% |
OWAPD |
|
Aripiprazole |
Tablet 10 mg |
Oral |
Y |
$28.47 |
N |
Y |
$28.47 |
$23.55 |
17.28% |
10% |
GWAPD |
|
Aripiprazole |
Tablet 15 mg |
Oral |
Y |
$40.40 |
N |
Y |
$40.40 |
$33.42 |
17.28% |
10% |
GWAPD |
|
Aripiprazole |
Tablet 20 mg |
Oral |
Y |
$49.18 |
N |
Y |
$49.18 |
$40.68 |
17.28% |
10% |
GWAPD |
|
Aripiprazole |
Tablet 30 mg |
Oral |
Y |
$59.93 |
N |
Y |
$59.93 |
$49.57 |
17.29% |
10% |
GWAPD |
|
Arsenic |
Injection concentrate containing arsenic trioxide 10 mg in 10 mL |
Injection |
Y |
$584.55 |
N |
Y |
$584.55 |
$473.37 |
19.02% |
10% |
GWAPD |
|
Atomoxetine |
Capsule 10 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$24.15 |
15.79% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 100 mg (as hydrochloride) |
Oral |
Y |
$37.29 |
N |
Y |
$37.29 |
$31.41 |
15.77% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 18 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$24.15 |
15.79% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 25 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$24.15 |
15.79% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 40 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$24.15 |
15.79% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 60 mg (as hydrochloride) |
Oral |
Y |
$28.68 |
N |
Y |
$28.68 |
$24.15 |
15.79% |
10% |
OWAPD |
|
Atomoxetine |
Capsule 80 mg (as hydrochloride) |
Oral |
Y |
$37.29 |
N |
Y |
$37.29 |
$31.41 |
15.77% |
10% |
OWAPD |
|
Atovaquone |
Oral suspension 750 mg per 5 mL, 210 mL |
Oral |
N |
- |
- |
- |
$873.50 |
$670.15 |
23.28% |
10% |
OWAPD |
|
Atovaquone with proguanil |
Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg |
Oral |
N |
- |
- |
- |
$46.03 |
$39.74 |
13.67% |
10% |
GWAPD |
|
Azacitidine |
Powder for injection 100 mg |
Injection |
Y |
$25.69 |
Y |
Y |
$25.69 |
$14.63 |
43.05% |
30% |
OWAPD |
|
Baclofen |
Tablet 10 mg |
Oral |
Y |
$9.28 |
N |
Y |
$9.28 |
$8.25 |
11.10% |
10% |
GWAPD |
|
Baclofen |
Tablet 25 mg |
Oral |
Y |
$20.28 |
N |
Y |
$20.28 |
$18.03 |
11.09% |
10% |
GWAPD |
|
Bevacizumab |
Solution for I.V. infusion 100 mg in 4 mL |
Injection |
N |
- |
- |
- |
$53.82 |
$41.71 |
22.50% |
10% |
OWAPD |
|
Bevacizumab |
Solution for I.V. infusion 400 mg in 16 mL |
Injection |
N |
- |
- |
- |
$215.28 |
$166.84 |
22.50% |
10% |
OWAPD |
|
Bortezomib |
Powder for injection 3 mg |
Injection |
N |
- |
- |
- |
$389.92 |
$286.63 |
26.49% |
10% |
OWAPD |
|
Buprenorphine |
Transdermal patch 10 mg |
Transdermal |
Y |
$12.62 |
N |
Y |
$12.62 |
$10.53 |
16.56% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 15 mg |
Transdermal |
Y |
$16.04 |
N |
Y |
$16.04 |
$13.39 |
16.52% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 20 mg |
Transdermal |
Y |
$19.47 |
N |
Y |
$19.47 |
$16.25 |
16.54% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 25 mg |
Transdermal |
Y |
$22.71 |
N |
Y |
$22.71 |
$18.95 |
16.56% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 30 mg |
Transdermal |
Y |
$25.95 |
N |
Y |
$25.95 |
$21.66 |
16.53% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 40 mg |
Transdermal |
Y |
$32.45 |
N |
Y |
$32.45 |
$27.08 |
16.55% |
10% |
GWAPD |
|
Buprenorphine |
Transdermal patch 5 mg |
Transdermal |
Y |
$7.01 |
N |
Y |
$7.01 |
$5.85 |
16.55% |
10% |
GWAPD |
|
Cabazitaxel |
Solution concentrate for I.V. infusion 60 mg in 3 mL |
Injection |
Y |
$88.67 |
N |
Y |
$88.67 |
$71.00 |
19.93% |
10% |
OWAPD |
|
Cabazitaxel |
Solution concentrate for I.V. infusion 60 mg in 6 mL |
Injection |
Y |
$88.67 |
N |
Y |
$88.67 |
$71.00 |
19.93% |
10% |
OWAPD |
|
Cinacalcet |
Tablet 30 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$19.75 |
$15.66 |
20.71% |
10% |
OWAPD |
|
Cinacalcet |
Tablet 60 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$39.51 |
$31.33 |
20.70% |
10% |
OWAPD |
|
Cinacalcet |
Tablet 90 mg (as hydrochloride) |
Oral |
N |
- |
- |
- |
$59.26 |
$46.99 |
20.71% |
10% |
OWAPD |
|
Clindamycin |
Capsule 150 mg (as hydrochloride) |
Oral |
Y |
$4.17 |
N |
Y |
$4.17 |
$4.00 |
11.75% |
10% |
GWAPD |
|
Dabigatran etexilate |
Capsule 110 mg (as mesilate) |
Oral |
N |
- |
- |
- |
$5.53 |
$4.57 |
17.36% |
10% |
OWAPD |
|
Dabigatran etexilate |
Capsule 150 mg (as mesilate) |
Oral |
N |
- |
- |
- |
$32.94 |
$27.21 |
17.40% |
10% |
OWAPD |
|
Darunavir |
Tablet 600 mg |
Oral |
N |
- |
- |
- |
$662.53 |
$577.86 |
12.78% |
10% |
OWAPD |
|
Darunavir |
Tablet 800 mg |
Oral |
N |
- |
- |
- |
$441.68 |
$385.23 |
12.78% |
10% |
OWAPD |
|
Darunavir |
Tablet 800 mg (as ethanolate) |
Oral |
N |
- |
- |
- |
$441.68 |
$385.23 |
12.78% |
10% |
OWAPD |
|
Deferasirox |
Tablet 180 mg |
Oral |
Y |
$29.02 |
Y |
Y |
$29.02 |
$4.38 |
84.91% |
30% |
GWAPD |
|
Deferasirox |
Tablet 360 mg |
Oral |
Y |
$58.04 |
Y |
Y |
$58.04 |
$8.75 |
84.92% |
30% |
GWAPD |
|
Deferasirox |
Tablet 90 mg |
Oral |
Y |
$14.51 |
Y |
Y |
$14.51 |
$4.00 |
84.91% |
30% |
GWAPD |
|
Deferasirox |
Tablet, dispersible, 250 mg |
Oral |
Y |
$136.45 |
N |
Y |
$136.45 |
$20.58 |
84.92% |
30% |
GWAPD |
|
Deferasirox |
Tablet, dispersible, 500 mg |
Oral |
Y |
$395.78 |
N |
Y |
$395.78 |
$59.68 |
84.92% |
30% |
GWAPD |
|
Dimethyl fumarate |
Capsule (modified release) 120 mg |
Oral |
N |
- |
- |
- |
$114.62 |
$90.57 |
20.98% |
10% |
GWAPD |
|
Enoxaparin |
Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$71.24 |
$63.67 |
10.63% |
10% |
OWAPD |
|
Enoxaparin |
Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$80.59 |
$72.02 |
10.63% |
10% |
OWAPD |
|
Enoxaparin |
Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$100.74 |
$90.03 |
10.63% |
10% |
OWAPD |
|
Enoxaparin |
Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$26.12 |
$23.34 |
10.64% |
10% |
OWAPD |
|
Enoxaparin |
Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$29.19 |
$26.09 |
10.62% |
10% |
OWAPD |
|
Enoxaparin |
Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$50.53 |
$45.16 |
10.63% |
10% |
OWAPD |
|
Enoxaparin |
Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$53.72 |
$48.01 |
10.63% |
10% |
OWAPD |
|
Fenofibrate |
Tablet 145 mg |
Oral |
Y |
$6.95 |
N |
Y |
$6.95 |
$5.91 |
14.96% |
10% |
GWAPD |
|
Fenofibrate |
Tablet 48 mg |
Oral |
Y |
$4.64 |
N |
Y |
$4.64 |
$4.00 |
14.87% |
10% |
GWAPD |
|
Fosaprepitant |
Powder for I.V. infusion 150 mg |
Injection |
N |
- |
- |
- |
$58.22 |
$47.63 |
18.19% |
10% |
GWAPD |
|
Fulvestrant |
Injection 250 mg in 5 mL pre-filled syringe |
Injection |
N |
- |
- |
- |
$134.60 |
$117.55 |
12.67% |
10% |
GWAPD |
|
Hydromorphone |
Injection containing hydromorphone hydrochloride 10 mg in 1 mL |
Injection |
N |
- |
- |
- |
$7.52 |
$6.06 |
19.41% |
10% |
OWAPD |
|
Hydromorphone |
Injection containing hydromorphone hydrochloride 2 mg in 1 mL |
Injection |
N |
- |
- |
- |
$5.64 |
$4.55 |
19.33% |
10% |
OWAPD |
|
Indapamide |
Tablet containing indapamide hemihydrate 2.5 mg |
Oral |
Y |
$4.14 |
N |
Y |
$4.14 |
$4.00 |
12.08% |
10% |
GWAPD |
|
Lamotrigine |
Tablet 100 mg |
Oral |
Y |
$9.13 |
N |
Y |
$9.13 |
$7.84 |
14.13% |
10% |
GWAPD |
|
Lamotrigine |
Tablet 200 mg |
Oral |
Y |
$15.35 |
N |
Y |
$15.35 |
$13.18 |
14.14% |
10% |
GWAPD |
|
Lamotrigine |
Tablet 50 mg |
Oral |
Y |
$5.48 |
N |
Y |
$5.48 |
$4.71 |
14.05% |
10% |
GWAPD |
|
Lanreotide |
Injection 120 mg (as acetate) in single dose pre-filled syringe |
Injection |
N |
- |
- |
- |
$1,290.76 |
$1,099.86 |
14.79% |
10% |
GWAPD |
|
Lanreotide |
Injection 90 mg (as acetate) in single dose pre-filled syringe |
Injection |
N |
- |
- |
- |
$1,130.87 |
$963.61 |
14.79% |
10% |
GWAPD |
|
Latanoprost with timolol |
Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL |
Application to the eye |
Y |
$7.58 |
N |
Y |
$7.58 |
$5.85 |
22.82% |
10% |
GWAPD |
|
Leflunomide |
Tablet 10 mg |
Oral |
Y |
$11.88 |
N |
Y |
$11.88 |
$10.15 |
14.56% |
10% |
GWAPD |
|
Leflunomide |
Tablet 20 mg |
Oral |
Y |
$18.09 |
N |
Y |
$18.09 |
$15.45 |
14.59% |
10% |
GWAPD |
|
Lenalidomide |
Capsule 10 mg |
Oral |
N |
- |
- |
- |
$400.72 |
$325.55 |
18.76% |
10% |
OWAPD |
|
Lenalidomide |
Capsule 15 mg |
Oral |
N |
- |
- |
- |
$482.63 |
$392.09 |
18.76% |
10% |
OWAPD |
|
Lenalidomide |
Capsule 25 mg |
Oral |
N |
- |
- |
- |
$631.44 |
$512.99 |
18.76% |
10% |
OWAPD |
|
Lenalidomide |
Capsule 5 mg |
Oral |
N |
- |
- |
- |
$305.88 |
$248.50 |
18.76% |
10% |
OWAPD |
|
Levodopa with carbidopa and entacapone |
Tablet 100 mg-25 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$56.96 |
$44.14 |
22.51% |
10% |
GWAPD |
|
Levodopa with carbidopa and entacapone |
Tablet 125 mg-31.25 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$59.12 |
$45.81 |
22.51% |
10% |
GWAPD |
|
Levodopa with carbidopa and entacapone |
Tablet 150 mg-37.5 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$62.35 |
$48.32 |
22.50% |
10% |
GWAPD |
|
Levodopa with carbidopa and entacapone |
Tablet 200 mg-50 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$67.31 |
$52.16 |
22.51% |
10% |
GWAPD |
|
Levodopa with carbidopa and entacapone |
Tablet 50 mg-12.5 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$51.57 |
$39.96 |
22.51% |
10% |
GWAPD |
|
Levodopa with carbidopa and entacapone |
Tablet 75 mg-18.75 mg (as monohydrate)-200 mg |
Oral |
N |
- |
- |
- |
$53.94 |
$41.80 |
22.51% |
10% |
GWAPD |
|
Metoprolol succinate |
Tablet 190 mg (controlled release) |
Oral |
Y |
$26.47 |
N |
Y |
$26.47 |
$23.70 |
10.46% |
10% |
GWAPD |
|
Metoprolol succinate |
Tablet 47.5 mg (controlled release) |
Oral |
Y |
$16.94 |
N |
Y |
$16.94 |
$15.17 |
10.45% |
10% |
GWAPD |
|
Metoprolol succinate |
Tablet 95 mg (controlled release) |
Oral |
Y |
$21.17 |
N |
Y |
$21.17 |
$18.95 |
10.49% |
10% |
GWAPD |
|
Moclobemide |
Tablet 150 mg |
Oral |
Y |
$6.14 |
N |
Y |
$6.14 |
$5.21 |
15.15% |
10% |
GWAPD |
|
Moclobemide |
Tablet 300 mg |
Oral |
Y |
$10.24 |
N |
Y |
$10.24 |
$8.70 |
15.04% |
10% |
GWAPD |
|
Modafinil |
Tablet 100 mg |
Oral |
Y |
$55.60 |
N |
Y |
$55.60 |
$48.37 |
13.00% |
10% |
GWAPD |
|
Moxonidine |
Tablet 200 micrograms |
Oral |
Y |
$4.22 |
N |
Y |
$4.22 |
$4.00 |
16.11% |
10% |
GWAPD |
|
Moxonidine |
Tablet 400 micrograms |
Oral |
Y |
$7.19 |
N |
Y |
$7.19 |
$6.02 |
16.27% |
10% |
GWAPD |
|
Mycophenolic acid |
Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL |
Oral |
Y |
$244.51 |
N |
Y |
$244.51 |
$186.10 |
23.89% |
10% |
GWAPD |
|
Mycophenolic acid |
Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid |
Oral |
Y |
$171.56 |
N |
Y |
$171.56 |
$130.57 |
23.89% |
10% |
GWAPD |
|
Olmesartan with hydrochlorothiazide |
Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg |
Oral |
Y |
$5.49 |
N |
Y |
$5.49 |
$4.72 |
14.03% |
10% |
GWAPD |
|
Olmesartan with hydrochlorothiazide |
Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg |
Oral |
Y |
$6.20 |
N |
Y |
$6.20 |
$5.33 |
14.03% |
10% |
GWAPD |
|
Paclitaxel, nanoparticle albumin-bound |
Powder for I.V. injection containing 100 mg paclitaxel |
Injection |
N |
- |
- |
- |
$287.13 |
$217.82 |
24.14% |
10% |
OWAPD |
|
Palonosetron |
Injection 250 micrograms (as hydrochloride) in 5 mL |
Injection |
N |
- |
- |
- |
$9.91 |
$3.98 |
59.84% |
10% |
OWAPD |
|
Pegfilgrastim |
Injection 6 mg in 0.6 mL single use pre-filled syringe |
Injection |
Y |
$91.63 |
N |
Y |
$91.63 |
$77.52 |
15.40% |
10% |
OWAPD |
|
Pemetrexed |
Powder for I.V. infusion 500 mg (as disodium) |
Injection |
Y |
$36.99 |
N |
Y |
$36.99 |
$23.57 |
36.28% |
30% |
OWAPD |
|
Pomalidomide |
Capsule 1 mg |
Oral |
N |
- |
- |
- |
$430.49 |
$264.06 |
38.66% |
10% |
GWAPD |
|
Pomalidomide |
Capsule 2 mg |
Oral |
N |
- |
- |
- |
$767.38 |
$470.72 |
38.66% |
10% |
GWAPD |
|
Pomalidomide |
Capsule 3 mg |
Oral |
N |
- |
- |
- |
$1,151.07 |
$706.08 |
38.66% |
10% |
GWAPD |
|
Pomalidomide |
Capsule 4 mg |
Oral |
N |
- |
- |
- |
$1,534.76 |
$941.43 |
38.66% |
10% |
GWAPD |
|
Pregabalin |
Capsule 150 mg |
Oral |
Y |
$7.19 |
N |
Y |
$7.19 |
$5.94 |
17.39% |
10% |
GWAPD |
|
Pregabalin |
Capsule 300 mg |
Oral |
Y |
$10.72 |
N |
Y |
$10.72 |
$8.85 |
17.44% |
10% |
GWAPD |
|
Pregabalin |
Capsule 75 mg |
Oral |
Y |
$4.68 |
N |
Y |
$4.68 |
$4.00 |
17.52% |
10% |
GWAPD |
|
Rivaroxaban |
Tablet 10 mg |
Oral |
N |
- |
- |
- |
$15.33 |
$11.39 |
25.70% |
10% |
OWAPD |
|
Rivaroxaban |
Tablet 15 mg |
Oral |
N |
- |
- |
- |
$26.99 |
$20.05 |
25.71% |
10% |
OWAPD |
|
Rivaroxaban |
Tablet 2.5 mg |
Oral |
N |
- |
- |
- |
$27.07 |
$20.11 |
25.71% |
10% |
OWAPD |
|
Rivaroxaban |
Tablet 20 mg |
Oral |
N |
- |
- |
- |
$26.66 |
$19.81 |
25.69% |
10% |
OWAPD |
|
Sevelamer |
Tablet containing sevelamer carbonate 800 mg |
Oral |
Y |
$158.81 |
N |
Y |
$158.81 |
$138.74 |
12.64% |
10% |
OWAPD |
|
Sitagliptin |
Tablet 100 mg |
Oral |
N |
- |
- |
- |
$19.33 |
$16.48 |
14.74% |
10% |
GWAPD |
|
Sitagliptin |
Tablet 25 mg |
Oral |
N |
- |
- |
- |
$19.33 |
$16.48 |
14.74% |
10% |
GWAPD |
|
Sitagliptin |
Tablet 50 mg |
Oral |
N |
- |
- |
- |
$19.33 |
$16.48 |
14.74% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride |
Oral |
N |
- |
- |
- |
$29.48 |
$24.15 |
18.08% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride |
Oral |
N |
- |
- |
- |
$30.47 |
$24.96 |
18.08% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride |
Oral |
N |
- |
- |
- |
$21.31 |
$17.46 |
18.07% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride |
Oral |
N |
- |
- |
- |
$20.33 |
$16.66 |
18.05% |
10% |
GWAPD |
|
Sitagliptin with metformin |
Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride |
Oral |
N |
- |
- |
- |
$21.01 |
$17.21 |
18.09% |
10% |
GWAPD |
|
Sunitinib |
Capsule 12.5 mg |
Oral |
N |
- |
- |
- |
$513.55 |
$456.65 |
11.08% |
10% |
GWAPD |
|
Sunitinib |
Capsule 25 mg |
Oral |
N |
- |
- |
- |
$1,033.58 |
$919.06 |
11.08% |
10% |
GWAPD |
|
Sunitinib |
Capsule 37.5 mg |
Oral |
N |
- |
- |
- |
$1,549.06 |
$1,377.42 |
11.08% |
10% |
GWAPD |
|
Sunitinib |
Capsule 50 mg |
Oral |
N |
- |
- |
- |
$2,092.68 |
$1,860.81 |
11.08% |
10% |
GWAPD |
|
Tacrolimus |
Capsule 0.75 mg |
Oral |
Y |
$98.08 |
N |
Y |
$98.08 |
$82.07 |
16.32% |
10% |
GWAPD |
|
Tamoxifen |
Tablet 20 mg (as citrate) |
Oral |
Y |
$4.97 |
N |
Y |
$4.97 |
$4.40 |
11.47% |
10% |
GWAPD |
|
Temozolomide |
Capsule 100 mg |
Oral |
Y |
$59.70 |
N |
Y |
$59.70 |
$48.19 |
19.28% |
10% |
GWAPD |
|
Temozolomide |
Capsule 140 mg |
Oral |
Y |
$82.33 |
N |
Y |
$82.33 |
$66.46 |
19.28% |
10% |
GWAPD |
|
Temozolomide |
Capsule 20 mg |
Oral |
Y |
$13.93 |
N |
Y |
$13.93 |
$11.24 |
19.31% |
10% |
GWAPD |
|
Temozolomide |
Capsule 250 mg |
Oral |
Y |
$141.84 |
N |
Y |
$141.84 |
$114.49 |
19.28% |
10% |
GWAPD |
|
Tenofovir |
Tablet containing tenofovir disoproxil fumarate 300 mg |
Oral |
Y |
$77.46 |
N |
Y |
$77.46 |
$56.54 |
27.01% |
10% |
GWAPD |
|
Tenofovir |
Tablet containing tenofovir disoproxil maleate 300 mg |
Oral |
Y |
$53.38 |
N |
Y |
$53.38 |
$38.96 |
27.01% |
10% |
GWAPD |
|
Tenofovir |
Tablet containing tenofovir disoproxil phosphate 291 mg |
Oral |
Y |
$53.38 |
N |
Y |
$53.38 |
$38.96 |
27.01% |
10% |
GWAPD |
|
Teriflunomide |
Tablet 14 mg |
Oral |
Y |
$96.50 |
N |
Y |
$96.50 |
$80.13 |
16.96% |
10% |
OWAPD |
|
Topiramate |
Tablet 100 mg |
Oral |
Y |
$9.72 |
N |
Y |
$9.72 |
$8.27 |
14.92% |
10% |
OWAPD |
|
Topiramate |
Tablet 200 mg |
Oral |
Y |
$16.34 |
N |
Y |
$16.34 |
$13.91 |
14.87% |
10% |
OWAPD |
|
Topiramate |
Tablet 50 mg |
Oral |
Y |
$6.18 |
N |
Y |
$6.18 |
$5.26 |
14.89% |
10% |
OWAPD |
|
Trastuzumab |
Powder for I.V. infusion 150 mg |
Injection |
Y |
$123.75 |
N |
Y |
$123.75 |
$105.18 |
15.01% |
10% |
OWAPD |
|
Trastuzumab |
Powder for I.V. infusion 440 mg with diluent |
Injection |
Y |
$320.29 |
N |
Y |
$320.29 |
$272.21 |
15.01% |
10% |
OWAPD |
|
Valganciclovir |
Tablet 450 mg (as hydrochloride) |
Oral |
Y |
$238.11 |
N |
Y |
$238.11 |
$188.44 |
20.86% |
10% |
OWAPD |
|
Vancomycin |
Capsule 125 mg (125,000 I.U.) (as hydrochloride) |
Oral |
N |
- |
- |
- |
$44.16 |
$39.19 |
11.25% |
10% |
GWAPD |
|
Vancomycin |
Capsule 250 mg (250,000 I.U.) (as hydrochloride) |
Oral |
N |
- |
- |
- |
$88.30 |
$78.36 |
11.26% |
10% |
GWAPD |
|
Varenicline |
Box containing 11 tablets 0.5 mg and 42 tablets 1 mg |
Oral |
N |
- |
- |
- |
$45.35 |
$32.59 |
28.14% |
10% |
OWAPD |
|
Varenicline |
Tablet 1 mg |
Oral |
N |
- |
- |
- |
$53.46 |
$38.42 |
28.13% |
10% |
OWAPD |
|
Voriconazole |
Tablet 200 mg |
Oral |
Y |
$168.54 |
N |
Y |
$168.54 |
$128.24 |
23.91% |
10% |
OWAPD |
|
Voriconazole |
Tablet 50 mg |
Oral |
Y |
$42.13 |
N |
Y |
$42.13 |
$32.06 |
23.90% |
10% |
OWAPD |
|
Zoledronic acid |
Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL |
Injection |
Y |
$57.23 |
N |
Y |
$57.23 |
$31.95 |
44.17% |
30% |
GWAPD |
Flow-on price disclosure reductions
A list of brands of pharmaceutical items that will be subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 April 2026 will be published soon. Sponsors are able to apply for Ministerial discretion for these reductions to be reduced or not apply. For more information see Ministerial Discretion.
Indicative prices of brands scheduled for a price disclosure reduction
The indicative prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in this cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day.
The indicative prices report will be published in January 2026.
Confirmed prices of brands scheduled for a price disclosure reduction
The Confirmed Prices Report outlines the approved ex‑manufacturer prices (AEMPs) for brands scheduled to take a price disclosure reduction.
The confirmed prices report will be published in March 2026.
Brand price reductions and savings to patients
The Brand Price Reductions and Savings to Patients Report outlines the price disclosure reductions per brand and potential savings to non-concessional patients from 1 April 2026. This information is made available to assist patients understand how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day.
The brand price reductions report will be published in March 2026.




